Metro North Hospital and Health Service

health.qld.gov.au

Metro North Hospital and Health Service (HHS) provides the full range of public sector health services including rural, regional and tertiary teaching hospitals. The HHS covers an area of 4157 square kilometres and extends from the Brisbane River to north of Kilcoy.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

PACBIO ACQUIRES OMNIOME, A DNA SEQUENCING STARTUP, FOR UP TO $800 MILLION

PacBio | July 26, 2021

news image

Pacific Biosciences has had no trouble growing its business on its own in the year and a half since its acquisition by Illumina was blocked by the Federal Trade Commission due to concerns that the combination would establish a monopoly in DNA sequencing. Earlier this year, the sequencer manufacturer received a staggering $900 million investment from SoftBank—a commitment almost as large as the $1.2 billion promised by Illumina for the planned acquisition. PacB...

Read More

Cell and Gene Therapy

EXUMA BIOTECH COMPLETES SERIES B2 TO ADVANCE NOVEL CELL & GENE THERAPIES

EXUMA Biotech Corp. | December 22, 2021

news image

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

Read More

Industry Outlook

ENVEDA BIOSCIENCES UNVEILS NEW AI ALGORITHM TO UNLOCK NATURE’S CHEMICAL CODE

Businesswire | June 26, 2023

news image

Enveda Biosciences, a biotechnology company discovering new medicines from natural sources, released the details of one of its foundational AI models, MS2Mol, in a pre-print posted on ChemRxiv. MS2Mol is designed to predict the structure of metabolites, which are the building blocks and breakdown products of the cell. Despite their essential role in all cell processes, it is estimated that less than 1% of all naturally-occurring metabolites are known to science. The ability of MS2Mol to ra...

Read More

THE LYNX GROUP ACQUIRES UPSTREAM PARTNERS TO CREATE A DYNAMIC DIVISION CATERING DIRECTLY TO THE PHARMACEUTICAL AND BIOTECH SPACE

The Lynx Group | August 14, 2020

news image

The Lynx Group (TLG) has acquired Upstream Partners in an effort to create a dynamic division catering directly to the pharmaceutical and biotech space. The ability to leverage the deep experiences and broad networks of both companies with external healthcare decision-makers and influencers together, allows the new division of TLG to provide pharmaceutical and biotech clients with thorough, market-informed perspectives needed throughout a product's life cycle. These insights are invaluable f...

Read More
news image

Cell and Gene Therapy

PACBIO ACQUIRES OMNIOME, A DNA SEQUENCING STARTUP, FOR UP TO $800 MILLION

PacBio | July 26, 2021

Pacific Biosciences has had no trouble growing its business on its own in the year and a half since its acquisition by Illumina was blocked by the Federal Trade Commission due to concerns that the combination would establish a monopoly in DNA sequencing. Earlier this year, the sequencer manufacturer received a staggering $900 million investment from SoftBank—a commitment almost as large as the $1.2 billion promised by Illumina for the planned acquisition. PacB...

Read More
news image

Cell and Gene Therapy

EXUMA BIOTECH COMPLETES SERIES B2 TO ADVANCE NOVEL CELL & GENE THERAPIES

EXUMA Biotech Corp. | December 22, 2021

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

Read More
news image

Industry Outlook

ENVEDA BIOSCIENCES UNVEILS NEW AI ALGORITHM TO UNLOCK NATURE’S CHEMICAL CODE

Businesswire | June 26, 2023

Enveda Biosciences, a biotechnology company discovering new medicines from natural sources, released the details of one of its foundational AI models, MS2Mol, in a pre-print posted on ChemRxiv. MS2Mol is designed to predict the structure of metabolites, which are the building blocks and breakdown products of the cell. Despite their essential role in all cell processes, it is estimated that less than 1% of all naturally-occurring metabolites are known to science. The ability of MS2Mol to ra...

Read More
news image

THE LYNX GROUP ACQUIRES UPSTREAM PARTNERS TO CREATE A DYNAMIC DIVISION CATERING DIRECTLY TO THE PHARMACEUTICAL AND BIOTECH SPACE

The Lynx Group | August 14, 2020

The Lynx Group (TLG) has acquired Upstream Partners in an effort to create a dynamic division catering directly to the pharmaceutical and biotech space. The ability to leverage the deep experiences and broad networks of both companies with external healthcare decision-makers and influencers together, allows the new division of TLG to provide pharmaceutical and biotech clients with thorough, market-informed perspectives needed throughout a product's life cycle. These insights are invaluable f...

Read More